(CercleFinance.com) – UBS reaffirms its ‘buy’ recommendation on Lonza Group as well as its target price of 630 Swiss francs, a target which implies a potential upside of 27% for the title of the Swiss group of chemicals and sub- pharmaceutical processing.
Following a roadshow with the group’s leaders, the broker expressed ‘optimism about the prospects for commercial manufacturing’, but warned that ‘biotechnology financing challenges are likely to persist until 2024’.
Copyright © 2023 CercleFinance.com. All rights reserved.
The information and analyzes disseminated by Cercle Finance only constitute a decision-making aid for investors. The responsibility of Cercle Finance cannot be held directly or indirectly following the use of information and analyzes by readers. It is recommended that any uninformed person consult a professional adviser before any investment. This indicative information does not in any way constitute an incitement to sell or a solicitation to buy.
Did you like this article ? Share it with your friends with the buttons below.
